Patents by Inventor Yoichi Ozawa

Yoichi Ozawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11925639
    Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 12, 2024
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Hiroshi Kamiyama, Masahiro Matsuki
  • Publication number: 20240075410
    Abstract: There is provided a gas solution supply apparatus capable of preventing bubbles from being generated in use at a point-of-use even if gas solution to be provided to a point-of-use has a high concentration. The gas solution supply apparatus 1 includes: a gas dissolving unit 4 that dissolves a source gas in a source liquid to produce a first gas solution; a first gas-liquid separator 10 that stores the first gas solution produced and produces a second gas solution through gas-liquid separation of the first gas solution; a pressure reducer 17 that depressurizes the second gas solution produced in the first gas-liquid separator 10; and a second gas-liquid separator 12 that stores the depressurized second gas solution and produces a third gas solution through gas-liquid separation of the second gas solution. The third gas solution is supplied to a point-of-use.
    Type: Application
    Filed: August 2, 2023
    Publication date: March 7, 2024
    Inventors: Suguru OZAWA, Yuji ARAKI, Yoichi NAKAGAWA, Toshifumi WATANABE, Risa KIMURA, Ryuta KATO
  • Publication number: 20230330081
    Abstract: Provided is a pharmaceutical composition for treating a tumor, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxyl-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmaceutically acceptable salt, which is to be administered in combination with a PD-1 antagonist.
    Type: Application
    Filed: October 26, 2021
    Publication date: October 19, 2023
    Inventors: Taisuke HOSHI, Yu KATO, Yoichi OZAWA, Satoshi KAWANO, Kotaro KODAMA, Saori MIYANO
  • Publication number: 20220409724
    Abstract: The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.
    Type: Application
    Filed: October 28, 2020
    Publication date: December 29, 2022
    Applicants: Eisai R&D Management Co., Ltd., Merck Sharp & Dohme Corp., MSD International GmbH
    Inventors: Yoichi OZAWA, Yasuhiro FUNAHASHI, Yu KATO
  • Patent number: 11369623
    Abstract: The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: June 28, 2022
    Assignees: PRISM Pharma Co., Ltd., Eisai R&D Management Co., Ltd.
    Inventors: Takenao Odagami, Hiroyuki Kouji, Yoichi Ozawa, Yusaku Hori
  • Publication number: 20190388420
    Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
    Type: Application
    Filed: February 6, 2018
    Publication date: December 26, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Hiroshi Kamiyama, Masahiro Matsuki
  • Publication number: 20180244808
    Abstract: Provided is a method capable of efficiently producing a modified diene-based rubber, and a rubber composition and a tire with excellent low hysteresis loss property, durability, etc. The method for producing a modified diene-based rubber of this disclosure comprises: performing modification by adding a modifier into a solution of a diene-based rubber as raw material obtained by dissolving a diene-based rubber as raw material in a solvent, and removing the solvent and reacting the modifier with the diene-based rubber as raw material while exerting a mechanical shear force, to thereby generate a modified diene-based rubber. The rubber composition of this disclosure uses a modified diene-based rubber produced with the method for producing a modified diene-based rubber of this disclosure. The tire of this disclosure uses the rubber composition of this disclosure.
    Type: Application
    Filed: August 1, 2016
    Publication date: August 30, 2018
    Applicant: BRIDGESTONE CORPORATION
    Inventors: Toshihiro UCHIYAMA, Hajime KONDO, Yoichi OZAWA
  • Publication number: 20180185395
    Abstract: The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.
    Type: Application
    Filed: June 15, 2016
    Publication date: July 5, 2018
    Applicants: PRISM Pharma Co., Ltd., EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Takenao Odagami, Hiroyuki Kouji, Yoichi Ozawa, Yusaku Hori
  • Patent number: 9969812
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 15, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
  • Patent number: 9644052
    Abstract: In general the present invention provides a functionalized polymer prepared by a process comprising the steps of preparing a pseudo-living polymer by polymerizing conjugated monomer with a lanthanide-based catalyst, and reacting the pseudo-living polymer with a functionalizing agent defined by the formula (I) A-R1—Z?? (I) where R1 is a divalent bond or divalent organic group comprising from 0 to about 20 carbon atoms, A is a substituent that will undergo an addition reaction with a pseudo-living polymer, and Z is a substituent that will react or interact with silica or carbon black reinforcing fillers, with the proviso that A, R1, and Z are substituents that will not protonate a pseudo-living polymer.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: May 9, 2017
    Assignee: Bridgestone Corporation
    Inventors: Yoichi Ozawa, H. Jerrold Miller, Koji Masaki, Koichi Morita, Tatsuo Fujimaki, Tetsuya Omura, Takuo Sone, Iwakazu Hattori
  • Patent number: 9623705
    Abstract: The invention provides a method for producing a modified conjugated diene (co)polymer, the method including comprising: a modification reaction step including causing an organic silane compound to react with a conjugated diene (co)polymer having an active site at the active site, the organic silane compound having a characteristic group for forming a silanol group through hydrolysis and, in the vicinity of the characteristic group, (i) a functional group which binds the organic silane compound to the conjugated diene (co)polymer via addition to or substitution at the active site and which promotes reaction between the silanol group and a reinforcing filler after the addition or substitution reaction, or (ii) a functional group which promotes reaction between the silanol group and a reinforcing filler, and a hydrolyzation step performed after the modification reaction step; a modified conjugated diene (co)polymer having, at a molecular end of the conjugated diene (co)polymer, a silanol group, and a functional
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: April 18, 2017
    Assignee: BRIDGESTONE CORPORATION
    Inventors: Ken Tanaka, Noriko Mori, Yuki Itoh, Yoichi Ozawa, Ryuji Nakagawa, Junko Matsushita, Shigeaki Matsuo, Kouji Masaki, Fumihiro Shiraishi, Fuminori Oota
  • Publication number: 20170100367
    Abstract: The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.
    Type: Application
    Filed: May 27, 2015
    Publication date: April 13, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Makoto ASANO, Bruce A. LITTLEFIELD, Junji MATSUI, Martin OLIVO, Yoichi OZAWA, Yanke YU
  • Publication number: 20170096493
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
  • Patent number: 9527921
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: December 27, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
  • Publication number: 20160347858
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
    Type: Application
    Filed: April 14, 2016
    Publication date: December 1, 2016
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino
  • Publication number: 20150259452
    Abstract: In general the present invention provides a functionalized polymer prepared by a process comprising the steps of preparing a pseudo-living polymer by polymerizing conjugated monomer with a lanthanide-based catalyst, and reacting the pseudo-living polymer with a functionalizing agent defined by the formula (I) A-R1—Z??(I) where R1 is a divalent bond or divalent organic group comprising from 0 to about 20 carbon atoms, A is a substituent that will undergo an addition reaction with a pseudo-living polymer, and Z is a substituent that will react or interact with silica or carbon black reinforcing fillers, with the proviso that A, R1, and Z are substituents that will not protonate a pseudo-living polymer.
    Type: Application
    Filed: March 23, 2015
    Publication date: September 17, 2015
    Applicants: JSR CORPORATION, BRIDGESTONE CORPORATION
    Inventors: Yoichi OZAWA, H. Jerrold MILLER, Koji MASAKI, Koichi MORITA, Tatsuo FUJIMAKI, Tetsuyo OHUMURA, Takuo SONE, Iwakazu HATTORI
  • Patent number: 9056925
    Abstract: A process for producing a modified conjugated diene based polymer includes a step (a) of reacting a silicon compound with a conjugated diene based polymer having an active end so that the reaction takes place at the active end, the silicon compound having a protected primary amino group in the molecule thereof and a silicon atom to which a hydrocarbyloxy group and a reactive group are bonded, to thereby modify the active end, and a step (b) of performing condensation reaction, in the presence of a titanium compound serving as a titanium-based condensation-accelerating agent. A rubber composition contains the modified diene polymer, and a tire is produced from the rubber composition.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: June 16, 2015
    Assignees: BRIDGESTONE CORPORATION, JSR CORPORATION
    Inventors: Ken Tanaka, Kouji Masaki, Yoichi Ozawa, Eiji Suzuki, Christine M. Rademacher, Terrence E. Hogan, Takuo Sone, Takaomi Matsumoto
  • Patent number: 9033014
    Abstract: This invention relates to a rubber composition including a polyisoprene rubber having a very high cis-1,4-bond content and having an excellent balance between dynamic properties and processability, and more particularly to a rubber composition comprising as a rubber component (A) a synthetic polyisoprene rubber having a cis-1,4-bond content of not less than 99.0%, a 3,4-bond content of not more than 0.5% and a Mooney viscosity ML1+4 (100° C.) of 20-110 and (B) a natural rubber.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: May 19, 2015
    Assignee: Bridgestone Corporation
    Inventors: Eiju Suzuki, Yoichi Ozawa
  • Patent number: 8987362
    Abstract: In general the present invention provides a functionalized polymer prepared by a process comprising the steps of preparing a pseudo-living polymer by polymerizing conjugated monomer with a lanthanide-based catalyst, and reacting the pseudo-living polymer with a functionalizing agent defined by the formula (I) A-R1—Z??(I) where R1 is a divalent bond or divalent organic group comprising from 0 to about 20 carbon atoms, A is a substituent that will undergo an addition reaction with a pseudo-living polymer, and Z is a substituent that will react or interact with silica or carbon black reinforcing fillers, with the proviso that A, R1, and Z are substituents that will not protonate a pseudo-living polymer.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: March 24, 2015
    Inventors: Yoichi Ozawa, H. Jerrold Miller, Koji Masaki, Koichi Morita, Tatsuo Fujimaki, Tetsuyo Omura, Takuo Sone, Iwakazu Hattori
  • Patent number: 8962752
    Abstract: This invention relates to a rubber composition being excellent in the low heat buildup and fracture properties (resistance to crack growth). and more particularly to a rubber composition, characterized by compounding 10-100 parts by mass of an inorganic filler and/or carbon black based on 100 parts by mass of a rubber component including not less than 10 mass % of a modified conjugated diene-based polymer having a cis-1,4 bond content of not less than 90% and a vinyl bond content of not more than 1.2% and a primary amino group. In this case, the modified conjugated diene-based polymer is obtained by (1) reacting the predetermined conjugated diene-based polymer having an active terminal with a compound having two or more predetermined functional groups and (2) further reacting the resulting product with a compound having a primary amino group.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: February 24, 2015
    Assignee: Bridgestone Corporation
    Inventors: Junko Matsushita, Yoichi Ozawa